{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:02:22Z","timestamp":1792821742694,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s40265-013-0096-1","type":"journal-article","created":{"date-parts":[[2013,7,11]],"date-time":"2013-07-11T05:48:58Z","timestamp":1373521738000},"page":"1245-1254","source":"Crossref","is-referenced-by-count":195,"title":["Trametinib: First Global Approval"],"prefix":"10.1007","volume":"73","author":[{"given":"Cameron J. M.","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,12]]},"reference":[{"key":"96_CR1","unstructured":"American Cancer Society. Cancer facts and figures\u00a02013; 2013. http:\/\/www.cancer.org\/acs\/groups\/content\/@epidemiologysurveilance\/documents\/document\/acspc-036845.pdf (Accessed 14 Jun 2013)."},{"issue":"16","key":"96_CR2","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","volume":"118","author":"JA Jakob","year":"2012","unstructured":"Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118(16):4014\u201323.","journal-title":"Cancer"},{"issue":"6892","key":"96_CR3","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949\u201354.","journal-title":"Nature"},{"issue":"2","key":"96_CR4","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s11864-013-0226-8","volume":"14","author":"DB Johnson","year":"2013","unstructured":"Johnson DB, Sosman JA. Update on the targeted therapy of melanoma. Curr Treat Options Oncol. 2013;14(2):280\u201392.","journal-title":"Curr Treat Options Oncol"},{"key":"96_CR5","unstructured":"GlaxoSmithKline. Two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar\u00ae (dabrafenib) capsules and the first MEK-inhibitor Mekinist(Tm) (trametinib) tablets, approved by FDA as single-agent therapies [media release]; 29 May 2013. http:\/\/www.gsk.com\/media\/press-releases\/2013\/two-new-gsk-oral-oncology-treatments-braf-inhibitor-tafinlar-.html ."},{"key":"96_CR6","unstructured":"US FDA. Mekinist (trametinib) tablets: prescribing information; 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/204114s000lbl.pdf (Accessed 14 Jun 2013)."},{"issue":"4","key":"96_CR7","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1200\/JCO.2012.43.5966","volume":"31","author":"KB Kim","year":"2013","unstructured":"Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1\/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013;31(4):482\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"96_CR8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107\u201314.","journal-title":"N Engl J Med"},{"key":"96_CR9","unstructured":"GlaxoSmithKline. GSK announces European submission for MEK monotherapy and BRAF\/MEK combination therapy in metastatic melanoma [media release]; 7 Feb 2013. http:\/\/www.gsk.com\/media\/press-releases\/2013\/Regulatory-update-European-submission-MEK-monotherapy-BRAF-MEK-combination-therapy-metastatic-melanoma.html ."},{"key":"96_CR10","unstructured":"GlaxoSmithKline. GlaxoSmithKline starts phase III study to test combined BRAF\/MEK inhibition in patients with BRAF positive melanoma following surgery [media release]; 1 Feb 2013. http:\/\/www.gsk.com\/media\/press-releases\/2013\/glaxosmithkline-starts-phase-iii-study-to-test-combined-braf-mek.html ."},{"key":"96_CR11","unstructured":"GlaxoSmithKline. GSK announces start of phase III programme for combination of dabrafenib (GSK2118436) and trametinib (GSK1120212) in BRAF V600 mutation-positive metastatic cutaneous melanoma [media release]; 29 May 2012. http:\/\/www.gsk.com\/media\/press-releases\/2012\/gsk-announces-start-of-phase-iii-programme-for-combination-of-dabrafenib-gsk2118436-and-trametinib-gsk1120212-in-braf-v600-mutation-positive-metastatic-cutaneous-melanoma.html ."},{"issue":"18","key":"96_CR12","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694\u2013703.","journal-title":"N Engl J Med"},{"key":"96_CR13","unstructured":"Japan Tobacco. Japan Tobacco, GlaxoSmithKline conclude licensing agreement for new drug candidate [media release]; 20 Apr 2006. http:\/\/www.japancorp.net ."},{"issue":"12","key":"96_CR14","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.18632\/oncotarget.747","volume":"3","author":"T Yoshida","year":"2012","unstructured":"Yoshida T, Kakegawa J, Yamaguchi T, et al. Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1\/2. Oncotarget. 2012;3(12):1533\u201345.","journal-title":"Oncotarget"},{"key":"96_CR15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3389\/fgene.2013.00066","volume":"4","author":"CJ Stones","year":"2013","unstructured":"Stones CJ, Kim JE, Joseph WR, et al. Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors. Front Genet. 2013;4:66.","journal-title":"Front Genet"},{"issue":"3","key":"96_CR16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","volume":"14","author":"PA Ascierto","year":"2013","unstructured":"Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013;14(3):249\u201356.","journal-title":"Lancet Oncol"},{"key":"96_CR17","doi-asserted-by":"crossref","unstructured":"Infante JR, Fecher LA, Nallapareddy S, et al. Safety and efficacy results from the first-in-human study of the oral MEK 1\/2 inhibitor GSK1120212 [abstract no. 2503]. J Clin Oncol. 2010;28(15 Suppl. 1).","DOI":"10.1200\/jco.2010.28.15_suppl.2503"},{"issue":"5","key":"96_CR18","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","volume":"19","author":"DT Frederick","year":"2013","unstructured":"Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19(5):1225\u201331.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"96_CR19","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1158\/1535-7163.MCT-11-0989","volume":"11","author":"JG Greger","year":"2012","unstructured":"Greger JG, Eastman SD, Zhang V, et al. Combinations of BRAF, MEK, and PI3K\/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012;11(4):909\u201320.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"96_CR20","first-page":"846","volume":"25","author":"MS Carlino","year":"2012","unstructured":"Carlino MS, Gowrishankar K, Saunders CA, et al. Anti-proliferative effects of continued MAPK pathway inhibition following acquired resistance to dabrafenib and trametinib: implications for melanoma treatment beyond progression [abstract]. Pigment Cell Melanoma Res. 2012;25(6):846\u20137.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"12","key":"96_CR21","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/sj.bjc.6605714","volume":"102","author":"KH Paraiso","year":"2010","unstructured":"Paraiso KH, Fedorenko IV, Cantini LP, et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer. 2010;102(12):1724\u201330.","journal-title":"Br J Cancer"},{"key":"96_CR22","doi-asserted-by":"crossref","unstructured":"Morris EJ, Jha S, Restaino CR, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013. doi: 10.1158\/2159-8290.CD-13-0070 .","DOI":"10.1158\/2159-8290.CD-13-0070"},{"issue":"6","key":"96_CR23","first-page":"842","volume":"25","author":"M Andrews","year":"2012","unstructured":"Andrews M, Behren A, Chiohn F, et al. Colorectal cancer promoted in a melanoma patient receiving dabrafenib (GSK2118436) in combination with MEK1\/2 inhibitor trametinib (GSK1120212) [abstract]. Pigment Cell Melanoma Res. 2012;25(6):842.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"2","key":"96_CR24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1593\/neo.121712","volume":"15","author":"DM Walters","year":"2013","unstructured":"Walters DM, Lindberg JM, Adair SJ, et al. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor\/HER2 inhibitor lapatinib. Neoplasia (New York). 2013;15(2):143\u201355.","journal-title":"Neoplasia (New York)"},{"issue":"6","key":"96_CR25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/cas.12139","volume":"104","author":"M Watanabe","year":"2013","unstructured":"Watanabe M, Sowa Y, Yogosawa M, et al. Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells. Cancer Sci. 2013;104(6):687\u201393.","journal-title":"Cancer Sci"},{"issue":"8","key":"96_CR26","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","volume":"13","author":"JR Infante","year":"2012","unstructured":"Infante JR, Fecher LA, Falchook GS, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(8):773\u201381.","journal-title":"Lancet Oncol"},{"key":"96_CR27","unstructured":"Kassir N, Mouksassi M, Cox DS, et al. Population pharmacokinetics (PK) of trametinib (GSK1120212), a MEK inhibitor, in subjects with cancer [abstract no. PII-48]. Clin Pharmacol Ther. 2013;93 Suppl. 1:S69."},{"key":"96_CR28","unstructured":"Cox DS, Fang L, Bauman JW, et al. The effect of food on the single dose pharmacokinetics of a novel MEK inhibitor, trametinib, in subjects with solid tumors [abstract no. PI-49]. Clin Pharmacol Ther. 2013;93 Suppl. 1:S31\u20132."},{"key":"96_CR29","doi-asserted-by":"crossref","unstructured":"Infante JR, Patnaik A, Jones SF, et al. A phase IB study of the MEK inhibitor GSK1120212 combined with everolimus in patients with solid tumors: interim results [abstract no. B128]. Mol Cancer Ther. 2011;10(11 Suppl. 1).","DOI":"10.1158\/1535-7163.TARG-11-B128"},{"issue":"1","key":"96_CR30","first-page":"154","volume":"26","author":"D Schadendorf","year":"2013","unstructured":"Schadendorf D, Milhem M, Demidov LV, et al. Trametinib (T) vs chemotherapy (C) in patients with BRAF V600E+ metastatic melanoma (MM): quality of life (QOL) analysis [abstract]. Pigment Cell Melanoma Res. 2013;26(1):154.","journal-title":"Pigment Cell Melanoma Res"},{"key":"96_CR31","unstructured":"Falchook G, Infante JR, Fecher LA, et al. The oral MEK 1\/2 inhibitor GSK1120212 demonstrates early efficacy signals [abstract no. 4847]. 35th Congress of the European Society for Medical Oncology, 8\u201312 Oct 2010;Milan."},{"issue":"9","key":"96_CR32","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.ejca.2013.03.020","volume":"49","author":"JR Infante","year":"2013","unstructured":"Infante JR, Papadopoulos KP, Bendell JC, et al. A phase 1b study of trametinib, an oral mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. Eur J Cancer. 2013;49(9):2077\u201385.","journal-title":"Eur J Cancer"},{"key":"96_CR33","doi-asserted-by":"crossref","unstructured":"Grilley-Olson JE, Bedard P, Fasolo A, et al. A phase I study of the MEK inhibitor GSK1120212 (GSK212) in combination with PI3K\/mTOR inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors [abstract no. B155]. AACR Molecular Targets and Cancer Therapeutics, 12\u201316 Nov 2011;San Francisco.","DOI":"10.1158\/1535-7163.TARG-11-B155"},{"key":"96_CR34","doi-asserted-by":"crossref","unstructured":"Corcoran RB, Falchook GS, Infante JR, et al. BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I\/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212) [abstract no. 3528]. J Clin Oncol. 2012;30(15 Suppl. 1).","DOI":"10.1200\/jco.2012.30.15_suppl.3528"},{"key":"96_CR35","doi-asserted-by":"crossref","unstructured":"Borthakur G, Popplewell L, Boyiadzis M, et al. Phase I\/II trial of the MEK1\/2 inhibitor trametinib (GSK1120212) in relapsed\/refractory myeloid malignancies: evidence of activity in patients with RAS mutation-positive disease [abstract no. 677]. Blood. 2012;120(21).","DOI":"10.1200\/jco.2011.29.15_suppl.6506"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0096-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0096-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0096-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T07:39:20Z","timestamp":1596094760000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0096-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["96"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0096-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}